Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure

被引:20
|
作者
Nakae, H
Narita, K
Endo, S
机构
[1] Akita Univ, Dept Emergency & Crit Care Med, Sch Med, Akita 0108543, Japan
[2] Iwate Med Univ, Crit Care & Emergency Ctr, Morioka, Iwate 020, Japan
关键词
D O I
10.1053/jcrc.2001.25470
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose: The Fas ligand (FasL)/Fas system is an apoptosis induction system that plays an important role in homeostasis and biophylaxis. We measured tumor necrosis factor alpha (TNF-alpha), soluble FasL (sFasL), and soluble Fas (sFas) in patients with acute hepatic failure to determine the relation between such failure and apoptosis. Materials and Methods: We assayed 21 blood samples from patients with acute hepatic failure and 8 from patients with sepsis but without acute hepatic failure. Serum TNF-a, sFas, and sFasL levels were determined by enzyme-linked immunosorbent assay. Results: sFasL levels were significantly higher in the patients with acute hepatic failure titan in the patients with sepsis (0.68 +/- 0.42 ng/mL vs. 0 ng/mL, P=.0001). No significant differences were observed in sFas levels between the two groups. A significant correlation was observed between TNF-alpha and sFas levels (r = 0.657, P = .0008); a negative correlation was observed between TNF-alpha and sFasL levels (r = 0.454, P = .038). Conclusions: Our results suggest that pathologic aggravation of acute hepatic failure are related to changes in the FasL/Fas system and that TNF-alpha and sFasL, in particular, may play hepatoprotective roles. Copyright (C) 2001 by WB. Sounders Company.
引用
下载
收藏
页码:59 / 63
页数:5
相关论文
共 50 条
  • [1] Serum Levels of Soluble Fas Ligand and Soluble Fas Receptor in Patients with Chronic Congestive Heart Failure
    李刚
    令狐华
    魏良明
    Chinese Medical Sciences Journal, 2002, (04) : 258 - 258
  • [2] The Serum Levels of Soluble Fas Ligand and Soluble Fas Receptor in Patients with chronic congestive heart failure
    李刚
    令狐华
    魏良明
    陈运贞
    South China Journal of Cardiology, 2002, (02) : 91 - 94
  • [3] Soluble Fas and soluble Fas L levels in patients with acute pancreatitis
    Endo, S
    Inoue, Y
    Fujino, Y
    Yamada, Y
    Sato, N
    Wakabayashi, G
    Sakamoto, T
    Ishikura, H
    Tanaka, T
    Inada, K
    Sato, S
    RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY, 2000, 108 (3-4) : 179 - 186
  • [4] Serum levels of soluble Fas ligand and Fas in patients with acute and fulminant hepatitis
    Suzuki, K
    Takikawa, Y
    Iwai, M
    Endo, R
    Abe, K
    Nakadate, I
    Kato, A
    Sato, S
    Yatomi, T
    Nakamura, N
    HEPATOLOGY, 1997, 26 (04) : 1921 - 1921
  • [5] Increased soluble Fas and Fas ligand levels in patients with nonalcoholic steatohepatitis
    Bhattacharyya, Tamali
    Yerian, Lisa
    Berk, Michael
    McCullough, Arthur
    Feldstein, Ariel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S122 - S122
  • [6] Serum levels of soluble Fas and soluble Fas ligand in patients with primary biliary cirrhosis.
    Deguchi, A
    Arima, K
    Nishioka, M
    HEPATOLOGY, 1999, 30 (04) : 566A - 566A
  • [7] Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease
    Takabatake, N
    Nakamura, H
    Inoue, S
    Terashita, K
    Yuki, H
    Kato, S
    Yasumura, S
    Tomoike, H
    RESPIRATORY MEDICINE, 2000, 94 (12) : 1215 - 1220
  • [8] Levels of soluble Fas but not soluble Fas ligand were elevated in the sera of patients with SLE.
    Okubo, M
    Ishida, H
    Nishimaki, T
    Yagita, H
    Okumura, KO
    Kasukawa, R
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 103 - 103
  • [9] Plasma Levels of Soluble Fas and Soluble Fas Ligand in Children with Nephrotic Syndrome
    M K Zahra
    N M Abu-El-Hanna
    Pediatric Research, 1999, 45 : 772 - 772
  • [10] Plasma levels of soluble Fas and soluble Fas ligand in children with nephrotic syndrome
    Zahra, MK
    Abu-El-Hanna, NM
    PEDIATRIC RESEARCH, 1999, 45 (05) : 772 - 772